Mesenchymal Stem Cells Market
Number of pages: 100 | Report Format: PDF | Published date: May 16, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 3.0 billion |
|
Revenue Forecast in 2031 |
US$ 8.5 billion |
|
CAGR |
12.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Products & Services ,Type, Indication ,Application and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global mesenchymal stem cells market was valued at US$ 3.0 billion in 2022 and is expected to register a revenue CAGR of 12.3% to reach US$ 8.5 billion by 2031.
Mesenchymal Stem Cells Market Fundamentals
Mesenchymal stem cells, or mesenchymal stromal cells (MSCs), are adult, multipotent cells that look like fibroblasts and can grow into mesodermal tissues like adipocytes, chondroblasts, and osteoblasts. Mesenchymal stem cells were first isolated from the bone marrow, then from cord cells, adipose tissue, and molar cells, among other places. MSCs are much more difficult to observe in histological sections due to their smaller size. Mesenchyme refers to a group of mesenchymal stem cells found throughout the body. Mesenchymal cells can duplicate in quantities of specific cells and fill in in-vitro or in-vivo conditions.
The immature mesenchymal microorganisms assume a significant part inside an organic entity for concealment of resistant cells enactment, increment the quantity of more up-to-date cells, lessen cell passing or cell harm in the body, and emission of both neurotrophic and angiogenic factors, which are liable for balancing out the extracellular grid, when relocated to the mind, this cells advance the decrease of free extreme levels and improve synaptic associations of harmed neurons, and expands the myelination of axons. Any damaged blood vessel in the cerebrum can also be replaced and repaired by mesenchymal cells.
The global mesenchymal stem cells industry analysis report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the Mesenchymal Stem Cells market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the mesenchymal stem cells market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
[25632]
Mesenchymal Stem Cells Market Dynamics
The aging population worldwide is expected to drive market expansion during the forecast period due to its increased susceptibility to diseases and disorders. Between 2015 and 2050, more than 60% of the world's population will double from 12% to 22%. In the meantime, starting around 2020, there were more individuals beyond 60 years old, and it is additionally expected that roughly 80% of the worldwide geriatric populace will abide in low-and center pay nations.
MSCs' potential as therapeutics for the treatment of inflammatory disorders is being looked into by many companies, which is helping the market grow. For instance, Takeda/TiGenix's phase 3 clinical trial uses MSCs to treat Crohn's disease complex perianal fistulas. As of September 2020, this is the most successful late-stage clinical trial. These factors are anticipated to increase the use of MSC products offered by major market players, intensifying market competition. The recent COVID-19 pandemic has shifted the focus of research and industry participants toward creating MSC-based therapeutics. MSCs can modulate the immune system, making them a potential treatment option for COVID-19-related respiratory infections.
More than 50 clinical trials have included MSCs in developing treatments for SARS-CoV-2 infection as of July 2020. MSCs are also being used in increasing research projects aimed at creating novel vaccine platforms. For instance, in June 2020, a group of experts in research from China presented a novel strategy for creating COVID-19 vaccines using engineered human MSCs with a positive antibody response that looked promising.
Wellsprings of undeveloped mesenchymal cells are utilized in clinical treatments. The market is anticipated to be driven by recent advancements in reproductive medicine by research using mesenchymal stem cells. For instance, in August 2022, Mesenchymal Stem Cell-Derived Exosomes as Nanodrug Carriers of Doxorubicin for Targeted Osteosarcoma Therapy via the SDF1-CXCR4 Axis. Osteosarcoma is the most common malignant bone tumor that primarily affect young people. Preoperative neoadjuvant chemotherapy, surgical resection of osteosarcoma tissue, and postoperative doxorubicin, cisplatin, and ifosfamide chemotherapy are the standard treatments.
Mesenchymal Stem Cells Market Ecosystem
Mesenchymal Stem Cells Market, by Product & Services
Mesenchymal Stem Cells Market, by Type
Mesenchymal Stem Cells Market, by Indication
Mesenchymal Stem Cells Market, by Application
Mesenchymal Stem Cells Market by Type
[2525]
The allogeneic MSCs held a significant revenue share of around 50% in 2022. MSCs from a donor rather than the patient's cells (autologous) are included in the segment. Development of the allogenic fragment can be ascribed to bringing down cost and quicker creation time contrasted with autologous MSCs. Allogenic MSCs can be efficiently manufactured and put away for some time later, making them all the more promptly accessible for clinical use. In addition, patients requiring multiple treatments or lacking viable autologous MSCs may benefit from allogeneic MSCs. This is credited to the high-security profile of allogeneic mesenchymal undifferentiated organisms in clinical applications. Due to their immunosuppressive and low immunogenicity, allogeneic MSC implantation is poised to become a ground-breaking cell-based therapeutic strategy. Allogeneic MSC implantations are more successful when there is a reduced immune response due to these properties.
The market segmentation sections provide the mesenchymal stem cells market outlook in terms of the demarcation of different consumer groups. Market segmentation is the split of an industry into subgroups depending on characteristics such as products & services ,type, indication ,application and other factors. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential mesenchymal stem cells market demand opportunities.
Mesenchymal Stem Cells Market by Region
The market was dominated by North America, which contributed around 38% revenue share in 2022. Many clinical trials are being conducted in the United States to determine whether mesenchymal stem cells can be used as a viable treatment for several life-threatening diseases. Additionally, many major companies involved in the supply and commercialization of MSCs have their headquarters in the United States, contributing to the region's market dominance.
During the forecast period, the Asia Pacific mesenchymal stem cells market is expected to grow fastest among other regions. The development of the market can be ascribed significantly to the rising mindfulness regarding medical services among individuals, alongside further developing medical services offices in the area supported by the increasing commonness of malignant growth. The close interaction of mesenchymal stem cells with cancer cells increases therapeutic sensitivity. Asia is thought to have a higher incidence of cancer cases and needs proper rehabilitation. For instance, nearly half of all cancer cases worldwide occur in Asia-Pacific. Additionally, it is anticipated that an increase in the prevalence of cardiovascular diseases like stroke, aortic, and other peripheral arterial diseases will boost market growth during the forecast period. CVDs, for instance, were responsible for approximately 10 million deaths in Asia in 2019.
Based on the regions, the global mesenchymal stem cells market is segmented into:
The industry's regional segmentation provides insights into geographic pockets regarding mesenchymal stem cells industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level mesenchymal stem cells market overview.
Key Components of the Report
Mesenchymal Stem Cells Market Competitive Landscape
Some of the prominent market players in the mesenchymal stem cells market include,
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Mesenchymal Stem Cells Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Mesenchymal stem cells, also known as mesenchymal stromal cells (MSCs), are adult, multipotent cells that look like fibroblasts and can grow into mesodermal tissues like adipocytes, chondroblasts, and osteoblasts.
The total mesenchymal stem cells market size worldwide in 2022 was US$ 3.0 billion in 2022.
The North America region will have the largest mesenchymal stem cells market size during the forecast period from 2023 to 2031.
The global mesenchymal stem cells is expected to grow at a revenue CAGR of 12.3% during the forecast period.
The resultant market size of the mesenchymal stem cells market in 2031 will be US$ 8.5 billion.
The global mesenchymal stem cells market will face additional challenges during the forecast period due to the high cost of treatment and lack of therapeutic advancements related to stem cell properties in vitro.
Market players focus on expanding their offerings through extensive R&D and forming alliances and partnerships with other major players to maintain their market position.
Some prominent market players in the mesenchymal stem cells market include Thermo Fisher Scientific, Inc., Cell Applications, Inc., and Cytori Therapeutics, Inc.
The allogeneic MSCs segment has the highest share in the global mesenchymal stem cells market.
*Insights on financial performance are subject to the availability of information in the public domain